Literature DB >> 14958824

Immunity to yellow fever nine years after vaccination with 17D vaccine.

G W A DICK, F L GEE.   

Abstract

Entities:  

Keywords:  YELLOW FEVER/prevention and control

Mesh：

Substances：

Year:  1952        PMID： 14958824     DOI： 10.1016/0035-9203(52)90062-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


× No keyword cloud information.
  11 in total

1.  Living modified viruses as immunizing agents.

Authors:  H R COX
Journal:  Br Med J       Date:  1954-07-31

Review 2.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

3.  A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

Authors:  William P Halford; Ringo Püschel; Edward Gershburg; Andrew Wilber; Svetlana Gershburg; Brandon Rakowski
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

4.  Serological survey for arboviruses in Uganda, 1967-69.

Authors:  B E Henderson; G B Kirya; L E Hewitt
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

5.  Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Authors:  Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

6.  The dissemination of 17D yellow fever vaccine in Africans in Kenya in relation to the interpretation of results of protection-test surveys.

Authors:  W H LUMSDEN
Journal:  Bull World Health Organ       Date:  1954       Impact factor: 9.408

7.  Recent rapid rise of a permethrin knock down resistance allele in Aedes aegypti in México.

Authors:  Gustavo Ponce García; Adriana E Flores; Ildefonso Fernández-Salas; Karla Saavedra-Rodríguez; Guadalupe Reyes-Solis; Saul Lozano-Fuentes; J Guillermo Bond; Mauricio Casas-Martínez; Janine M Ramsey; Julián García-Rejón; Marco Domínguez-Galera; Hilary Ranson; Janet Hemingway; Lars Eisen; William C Black IV
Journal:  PLoS Negl Trop Dis       Date:  2009-10-13

Review 8.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

Review 9.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

10.  An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge.

Authors:  Nicholas Svitek; Rosemary Saya; Elias Awino; Stephen Munyao; Robert Muriuki; Thomas Njoroge; Roger Pellé; Nicholas Ndiwa; Jane Poole; Sarah Gilbert; Vishvanath Nene; Lucilla Steinaa
Journal:  NPJ Vaccines       Date:  2018-09-11       Impact factor: 7.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.